Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer.

Trial Profile

Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs T-cell vaccine-AlloStim; T-cell vaccine-AlloStim; T-cell vaccine-AlloStim
  • Indications Advanced breast cancer; Cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2012 Results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to a Immunovative media release.
    • 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top